Format

Send to

Choose Destination
BMB Rep. 2010 Apr;43(4):233-44.

Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.

Author information

1
Institute for Brain Science & Technology/Graduate Program of Neuroscience, Inje University, Busan 614-735, Korea. wseol@inje.ac.kr

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2's mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PDcausing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s) and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2's therapeutic potential as a PD target gene will be discussed.

PMID:
20423607
DOI:
10.5483/bmbrep.2010.43.4.233
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Korean Society for Biochemistry and Molecular Biology
Loading ...
Support Center